

Title (en)
Compositions for minimizing the uterotrophic effect of tamoxifen and its analogs

Title (de)
Zusammensetzungen zur Minimierung des uterustrophischen Effekts von Tamoxifen und dessen Analogen

Title (fr)
Compositions pour réduire les effets utérotrrophiques du tamoxifène et de ses analogues

Publication
EP 0702961 A2 19960327 (EN)

Application
EP 95306539 A 19950918

Priority
US 30890494 A 19940920

Abstract (en)
The present invention provides a method of minimizing the uterotrophic effect of non-steroidal antiestrogen compounds of formula II <CHEM> wherein either R<4> is H or a lower alkyl radical and R<5> is a lower alkyl radical, or R<4> and R<5> are joined together with the adjacent nitrogen atom to form a heterocyclic radical; R<6> is H or a lower alkyl radical; R<7> is H, halo, OH, a lower alkyl radical, or is a buta-1,3-dienyl radical which together with the adjacent benzene ring forms a naphthyl radical; R<8> is H or OH; and n is 2; or a pharmaceutically acceptable salt thereof, wherein said formula II compound is administered to a woman for the treatment or prevention of breast carcinoma, comprising concurrently or sequentially administering to said woman a compound of formula I <CHEM> wherein R<1> is -H, -OH, -O(C1-C4 alkyl), -OCOC6H5, -OCO(C1-C6 alkyl), or -OSO2(C4-C6 alkyl); R<2> is -H, -OH, -O(C1-C4 alkyl), -OCOC6H5, -OCO(C1-C6 alkyl), or -OSO2(C4-C6 alkyl); n is 2 or 3; and R<3> is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino; or a pharmaceutically acceptable salt thereof. The present invention further provides pharmaceutical compositions comprising a compound of formula I and a compound of formula II together with a pharmaceutically acceptable carrier, excipient, or diluent.

IPC 1-7
A61K 45/06; A61K 31/135

IPC 8 full level
C07D 295/08 (2006.01); **A61K 31/135** (2006.01); **A61K 31/138** (2006.01); **A61K 31/40** (2006.01); **A61K 31/445** (2006.01); **A61K 31/452** (2006.01); **A61K 31/535** (2006.01); **A61K 31/5375** (2006.01); **A61K 31/55** (2006.01); **A61K 45/06** (2006.01); **A61P 13/02** (2006.01); **A61P 15/00** (2006.01); **A61P 35/00** (2006.01); **C07D 207/06** (2006.01)

CPC (source: EP KR US)
A61K 31/445 (2013.01 - KR); **A61K 31/535** (2013.01 - KR); **A61K 31/55** (2013.01 - KR); **A61K 45/06** (2013.01 - EP US); **A61P 13/02** (2017.12 - EP); **A61P 15/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP)

Cited by
CZ305571B6; EP0895989A1; US6509356B1; WO0204418A3

Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)
EP 0702961 A2 19960327; EP 0702961 A3 19991110; EP 0702961 B1 20020724; AT E220919 T1 20020815; AU 3686295 A 19960409; AU 692932 B2 19980618; CA 2200205 A1 19960328; CZ 82097 A3 19970813; DE 69527480 D1 20020829; FI 971155 A0 19970319; FI 971155 A 19970319; HU T77954 A 19981228; JP H10506111 A 19980616; KR 970705999 A 19971103; MX 9702037 A 19970628; NO 971229 D0 19970317; NO 971229 L 19970317; NZ 294176 A 19991028; RU 2158589 C2 20001110; US 5554628 A 19960910; WO 9609051 A1 19960328

DOCDB simple family (application)
EP 95306539 A 19950918; AT 95306539 T 19950918; AU 3686295 A 19950918; CA 2200205 A 19950918; CZ 82097 A 19950918; DE 69527480 T 19950918; FI 971155 A 19970319; HU 9801476 A 19950918; JP 51113195 A 19950918; KR 19970701745 A 19970318; MX 9702037 A 19950918; NO 971229 A 19970317; NZ 29417695 A 19950918; RU 97106107 A 19950918; US 30890494 A 19940920; US 9512345 W 19950918